Relapse after autologous bone marrow transplantation for chronic myelogenous leukemia (CML) can be due either t o the persistence of leukemia cells in systemic tissues following preparative therapy, or due to the persistence of leukemia cells in the autologous marrow used t o restore marrow function after intensive therapy.
Relapse after autologous bone marrow transplantation for chronic myelogenous leukemia (CML) can be due either t o the persistence of leukemia cells in systemic tissues following preparative therapy, or due to the persistence of leukemia cells in the autologous marrow used t o restore marrow function after intensive therapy.
To help distinguish between these two possible causes of relapse, we used safetymodified retroviruses, which contain the bacterial resistance gene NEO, t o mark autologous marrow cells that had been collected from patients early in the phase of hematopoietic recovery after in vivo chemotherapy. The cells were then subjected t o ex vivo CD34 selection following collection and 30% of the bone marrow were exposed t o a safety-modified virus. This marrow was infused after delivery of systemic therapy, which consisted of total body irradiation (1,020 cGy), cyclophosphamide (120 mg/kg), and VP-16 (750 mg/m2). RT PCR assays specific for the bacterial NE0 mRNA, which was coded for by the virus, and the bcr-ab/ mRNA showed that UR PREVIOUS experience in autologous bone marrow transplantation in late chronic phase chronic myelogenous leukemia (CML) patients, who are resistant to alphainterferon, or who lack an HLA-compatible allogeneic donor, has suggested that the probability of obtaining cytogenetic remissions with autologous transplants performed after total body irradiation, cyclophosphamide, and VP-16, is dependent on the percentage of diploid cells in the autologous bone marrow or peripheral blood cells that are infused.' Seventy-five percent of those patients in whom diploid cells are available at the time of marrow storage develop durable cytogenetic remissions after transplant, whereas only 25% of such patients developed cytogenetic remissions after transplant if their marrow was harvested at the time when 100% of the cells were Philadelphia chromosome-positive in two evaluable CML patients transplanted with marked cells, sufficient numbers of leukemia cells remained in the infused marrow t o contribute t o systemic relapse. In addition, both normal and leukemic cells positive for the retroviral transgenome persisted in the systemic circulation of the patients for at least 280 days posttransplant showing that the infused marrow was responsible for the return of hematopoiesis following the preparative therapy. This observation shows that it is possible t o use a replication-incompetent safety-moddied retrovirus in order t o introduce DNA sequences into the hematopoietic cells of patients undergoing autologous bone marrow transplantation. Moreover, this data suggested that additional fractionation procedures will be necessary t o reduce the probability of relapse after bone marrow transplantation in at least the advanced stages of the disease in CML patients undergoing autologous bone marrow transplantation procedures. 0 1994 by The American Society of Hematology.
(Ph'). In order to increase the probability of cytogenetic remissions after bone marrow transplantation, we have initiated a program, summarized in Table 1 , which involves three steps designed to reduce the level of contaminating leukemia cells in the preparations of autologous marrow and peripheral blood, both of which are used for transplant: (1) Delivery of conventional dose chemotherapy to reduce the ratio of Ph' to Ph-cells before the time of storage of autologous marrow or peripheral blood; (2) collection of peripheral blood progenitor cells early in the course of hematopoietic recovery, at a time when diploid cells dominate the peripheral blood, to reduce the level of leukemic cells in these preparations; and (3) ex vivo fractionation with the CellPro CEPRATE SC Stem Cell Concentrator (CD34 monoclonal antibody column).
We have been performing these programs in CML patients in chronic phase as well as in the accelerated phase and blast crisis. Our experience so far suggests that the use of in vivo chemotherapy and collection of the peripheral blood stem cells early in the phase of hematopoietic recovery is successful in generating engrafting doses of diploid hematopoietic progenitor cells, as two of the chronic and accelerated phase CML patients treated so far have developed cytogenetic remissions posttransplant, and four of 10 patients transplanted are in complete cytogenetic remission 3 to 8 months posttransplant. In contrast to the favorable experience with chronic phase and accelerated phase CML patients, no cytogenetic remissions have been achieved posttransplant with blast crisis patients. Now that it is possible to develop cytogenetic remissions in some but not all CML patients after bone marrow transplantation, it is appropriate to ask what is the origin of relapse after reconstitution with autologous marrow following ablative preparative therapy. To answer this question, we have used the GlNA safety-modified virus (provided by Genetic Therapy, Inc) for transduction of hematopoietic progenitor cells used for autologous transplant of second chronic phase CML patients (ie, those in whom conventional dose chemotherapy induced a chronic phase following evolution of accelerated phase or blast crisis). A similar marking vector has been used by Brenner et a1 to identify the origin of relapse following autologous transplants in acute myelogenous leukemia (AML) and neuroblastoma patients.24 Two features of our study were different from Brenner's study. (1) The cells for transplant were collected early in the recovery phase following conventional dose chemotherapy; and (2) CD34-positive selection using the CellPro CEPRATE SC Stem Cell Concentration was performed before transduction to remove the more mature cells so as to reduce the number of Ph' CML cells and to increase the transduction frequency.
Following autologous reconstitution, we used polymerase chain reaction (PCR) assays to measure the frequency of cells bearing the NE0 retroviral transgenome in the normal or chronic phase hematopoietic cells, which repopulate the marrow after autologous transplantation. In one case, it was possible to use reverse transcriptase-PCR (RT-PCR) on FACS-separated leukemic cells coupled with myeloid-specific cell culture techniques to show conclusively that the leukemia cells arising in the patient after transplant contained the NE0 viral transgene. These studies have indicated that it is possible to introduce in vitro retroviral sequences into sufficient numbers of hematopoietic progenitor cells to sustain circulating levels of normal or chronic phase CML cells, which are marked by the retrovirus for at least 280 days posttransplant, and that both normal and leukemic early precursor cells (long-term culture initiating cells) contained the viral sequences. In addition, these studies have shown that a sufficient number of cells are left in the autologous marrow used for transplant to contribute to systemic relapse. Description of Trial Eiigibility. Patients who were c 6 0 years old with accelerated phase or blast crisis or second chronic phase CML, who were interferon-resistant and who lacked an HLA-compatible allogeneic bone marrow transplant donor were eligible for this trial.
MATERIALS AND METHODS
Treatment program. Patients in accelerated phase or blast crisis were administered conventional dose chemotherapy, either high-dose cytosine arabinoside (1.5 @m* continuous infusion days 3 and 4) and daunomycin (120 mg/mz day 1) or fiudarabine (30 m@mZ1d for 3 days), cytosine arabinoside (l g/m2/d for 3 days as a 2-hour infusion), and mitoxantrone (10 mg/m2/d for 4 days) to reduce the ratio of leukemia to normal cells in the marrow. Peripheral blood cells were collected using continuous flow centrifugation during the early phases of hematopoietic recovery, starting on the day the white blood cell (WBC) count reached 1,2001pL, until 200 million nucleated cellskg were collected, and one or two of these collections were subjected to CD34-positive selection, using the CellPro CEPRATE SC Stem Cell Concentrator, such that at least 0.7 million CD34-positive cellskg were collected. Once the total WBC count reached 4,aoO/pL, the bone marrow was harvested, and subjected to CD34 selection as well.
Thirty percent of the CD34 selected bone marrow cells were exposed to the safety-modified virus under the conditions listed below, and 70% of the cells, which were not exposed to the virus, were frozen immediately.
The patient then received the preparative regimen of 1,020 cGy irradiation, 120 mglkg of cyclophosphamide, and 750 mg/mz of VP-16. Following delivery of the preparative regimen, the marked and unmarked CD34 selected bone marrow and the unmarked peripheral blood was infused. Following recovery of a platelet count of 50,0001 mm3 and a total WBC count of at least 2,500/pL, a-interferon at 1 to 3 million units subcutaneously per day was initiated.
Transduction procedures. Thirty percent of the autologous cells at lo7 cellslcc were suspended in the cell-free retroviral supernatant (lo5 MOUcc) for 6 hours. The cells were then centrifuged, frozen, and saved for transplant.
The method used for transduction was as follows: Cell-free retroviral supernatants, prepared by Genetic Therapy, Inc. were used for suspension of CD34 isolated by CellPro CEPRATE SC Stem Cell Concentrator, at a concentration of 10 infectious units per nucleated cell, for 6 hours, in the absence of growth factors or stromal monolayers. At the end of the incubation, the cells were centrifuged and rinsed twice and frozen with a programmed freezer.
An aliquot of the cells was plated in methylcellulose or plated in Dexter cultures for varying periods before plating in methylcellulose and grown for 14 days before RT-PCR assay. These transduction procedures were approved by the NIH Recombinant DNA Advisory Committee, pursuant regulations in place at the time of approval of the protocol in June 1992. The same protocol has been used by Dr Malcolm Brenne?" to study autologous transplants of AML patients.
PCR Assays
PCR assays were conducted as outlined in previous publications.6.' Extraction of the nucleic acid. Following harvesting of the colonies, the colony was delivered into an eppendorf that was nuclease free. Lysis was conducted in 100 lambda of "solution D," which consisted of 1.5 lambda of glycogen, 10 lambda of 2 mol& sodium acetate at pH 4.5, 100 lambda of phenol, and 20 lambda of chloroform. All subsequent steps were conducted on ice. The sample was vortexed and placed on ice for 15 minutes. The sample was then centrifuged at 10,oOOg for 10 minutes. The top clear phase was delivered into a new eppendorf centrifuge tube, and 100 lambda of isopropyl alcohol was added. The sample was stored at -20°C for 60 minutes or overnight. The samples were then centrifuged for 10 minutes at 10,oOog. The supernatant liquid was removed, and 150 lambda of 70% ethanol was added and washed until pellet is loosened. The pellet was centrifuged again at 10,OOOg for 6 minutes, the ethanol removed, and the pellet left to dry. The pellet was then For personal use only. on October 30, 2017. by guest www.bloodjournal.org From resuspended in 5 lambda of RT buffer (see next section). This procedure was the same for whole cells except that the initial lysis for one million cells used 500 lambda of solution D, which consisted of 1.5 lambda of glycogen, 50 lambda of 2.0 molk sodium acetate at pH 4.5.500 lambda of phenol, and 1 0 0 lambda of chloroform, and that 500 lambda of isopropyl alcohol was used for the precipitation.
RT reaction. The nucleic acid was dissolved in 1X RT buffer by mixing for 3 minutes at 94°C. and centrifuged. The supernatant was used for the RT reaction. The RT reaction was conducted in the 1 X reaction buffer, which consisted of 2.45 lambda of water, 1 lambda of 5x RT buffer, 0.2 lambda of dNTP (25 mmollUlambda), 0.25 of random hexamer (100 pmolAambda). 0.25 lambda of RNase inhibitor (40 UAambda), 0.25 lambda of Moloney murine leukemia virus RT (200 UAambda), 0.5 lambda of 0.1 molk dithiothreotol, and 0.1 lambda of bovine serum albumin (IO mg/mL). The nucleic acid dissolved in 5 lambda of RT buffer was added to 5 lambda of the above 1 X reaction buffer, mixed, and incubated for 60 minutes at 42°C. Following the reaction, the sample was centrifuged quickly, and 10 lambda of the supernatant, which contains the cDNA product, was delivered into each of the two eppendorf tubes, which already contained 40 lambda of PCR mixture buffer, and one drop of mineral oil.
The PCR mixture contains the following in 50 lambda: 34.55 lambda of water, 4 lambda of 1OX buffer, 0.2 lambda of dNTP (25 mmollUlambda), 0.5 lambda of the sense primer (25 pmolAambda), 0.5 lambda of antisense primer (25 pmolAambda), and 0.25 lambda of Taq polymerase (5 UAambda).
The cycle schedule for the sequence amplification is 1 cycle at 94°C for 4.5 minutes, then 45 cycles as follows: 30 seconds at 94°C. 30 seconds at %"C, and 60 seconds at 72°C. A final cycle for 10 minutes at 72°C is then conducted. 
CCCCA'ITGTGATTATAGCCTAAGACCCGGAGC.
The strategy used for the PCR is presented in Fig 1. We multiplied the percentage of colonies positive for NE0 times the number of colonies, which were G418 resistant, times the number of cells plated. This enabled us to compute the actual frequency of transduced colonies. This was in the 1% to 10% range. This data is presented in Tables 2 through 4 . These calculations of transduction frequency do not take into consideration that only 30% of the marrow is marked, and that both marrow and unmarked peripheral blood were used for the transplant.
RESULTS

In Vitro Transduction ESficiency
Marrow and peripheral blood cells from CML patients were collected early in the phase of recovery from the myelosuppressive effect of chemotherapy and subjected to CD34 selection using the CellPro CEPRATE Stem Cell Concentrator. Thirty percent of the CD34 selected marrow cells were incubated in a cell-free supernatant at a ratio of 10 focusforming unitdnucleated cell, at a concentration of lo6 cells/ cc in the absence of growth factors or stroma. We incubated the virus and cells for 6 hours following which the cells were washed twice and frozen with programmed freezing. In order to determine the frequency of transduction of clonogenic progenitor cells by the safety-modified retrovirus, we inoculated the cells in methylcellulose at different concentrations of G418, to which the retroviral gene, NEO, confers resistance. In order to test if the virus transduced early myeloid precursor cells [long-term culture-initiating cells (LTCIC)], we cultured some of the transduced cells in Dexter culture for 35 days or more, before plating in methylcellulose. As shown in Fig 1, the reverse transcriptase products were split into two halves, and one-half was analyzed by PCR with primers coding for actin and bcr-abl to distinguish between normal and leukemia cells, and the other half analyzed by a PCR assay with NE0 primers. As shown in Table   2 , the frequency of NEO-positive cells was 1% to 4% and the frequency was the same for both leukemic and nonleukemic cells.
In order to determine if cells at earlier stages of maturation were transduced by the virus and at what frequency, we cultured the cells following transduction in a long-term bone marrow culture (Dexter) system for more than 35 days. The The cells of patient no. 2 were grown in Dexter culture for 61 days between the time of retroviral marking and plating in methylcellulose. The percent of cells that were positive for the virus was calculated by multiplying the percent resistant to G418 selection by the percent of cells positive for NE0 by RT PCR assay. NEO-positive colonies were formed that were bcr-ab/ positive and negative.
cells extant in the culture and that time are termed LTCIC. Then, the cells were plated in methylcellulose following the long-term culture. The colonies derived from postvirally exposed cells, which had been maintained for long periods of time, arose from earlier precursors than those derived from colonies that were plated immediately following transduction.
As shown in Table 2 , there were NEO-positive cells in 3% of cells growing in the Dexter culture 61 days following inoculation indicating that the virus had transduced the LTCIC in that patient. Both the leukemic and nonleukemic populations up to 61 days of Dexter culture were marked in the blast crisis patient. The percentage of cells that were positive for a functional NE0 retroviral transgenome in colonies immediately plated following transduction was the same as the percentage of cells transduced when the colonies were derived from cells which had been maintained in culture for 5 to 9 weeks after transduction. This showed that early as well as late cells were transduced. * No colonies formed from the patient's blood or bone marrow after transplant. Therefore, the analyses were done on samples of cells, not colonies. The sensitivity of the RT-PCR assay is 1/100,000 cells. 
RT-PCR Studies of Colonies Derived From Cells of CML Patients Following Transplantation With Retrovirally Marked Cells
Description of patient no. l. This was a 40-year-old patient who presented with CML in the chronic phase 3 years before the autologous transplant. He had no sibling nor unrelated matched allograft donors. By 2 years after diagnosis (October 1991), the patient had received l 1 courses of homoharringtonine in an attempt to induce a cytogenetic remission. Following this therapy, he had achieved a minor cytogenetic response. Unfortunately, following completion of this therapy in November 1991, lymphoid blast crisis of CML was diagnosed, with 33% of a bone marrow aspirate taken on November 11, 1991 composed of lymphoblasts. During the succeeding 3 months, he received three cycles of cyclophosphamide, vincristine, ara-C, and dexamethasone (CVAD) for the lymphoid blast crisis, which induced a second chronic phase, as documented by a marrow aspirate. Three months later (March 1992), a bone marrow harvest was conducted and the cells were CD34 selected. That preparation contained very few CD34-positive DR-negative cells and was therefore deemed to contain predominantly leukemic cells. Following an additional cycle of CVAD, he received a cycle of daunomycin and high-dose ara-C in April 1992. The goal of this therapy was to further reduce the residual level of lymphoblasts in the marrow before collection of autologous peripheral blood and marrow. These cells were to be used to support the safe delivery of TBI, VP-16, and cyclophosphamide as a means to consolidate the second chronic phase of this disease. Following the daunomycin and ara-C chemotherapy, the peripheral blood stem cells were collected early in the course of recovery but were not marked. These peripheral blood stem cells were CD34 selected and stored. Unselected peripheral blood mononuclear cells, which were not marked nor fractionated, were also stored as a backup preparation of stem cells. These collections were completed in the early phases of hematopoietic recovery, since we have found that this increases the probability of obtaining diploid cells as reported by Carella et al.' All of these cells were Ph+, but no lymphoblasts were detectable by morphology. The bone mmow was re-harvested on June 18, 1992 and CD34 selected, and 30% of the cells were exposed to a safety-modified marking retrovirus obtained from Genetic Therapy, Inc. In late July, 1992, the patient was admitted for preparative therapy for bane marrow transplantation. The preparative regimen of TBI, VP-16, and cyclophosphamide was initiated on July 30, 1992. On August 7, 1992, the unmarked but CD34 selected peripheral blood stem cells from May 1992 and the retrovirally marked and unmarked CD34 selected marrow were also infused.
Results of RT-PCR studiesfor N E 0 in patient no. 1. As shown in Fig 2, the patient recovered a neutrophil count of 500/pL by 18 days posttransplant, and was in a minor cytogenetic remission (20% diploid cells and 80% Ph' cells) immediately posttransplant. This patient quickly became 100% positive for cells that were Ph+. No colonies grew from the peripheral blood or marrow of this patient during the 4 months following transplant during which he was in second chronic phase, or during the blast crisis phase which appeared in the fifth month after transplant. Absence of colony growth occurs in about 10% of CML patients following autologous bone marrow transplant. The failure to detect methylcellulose colonies in the peripheral blood and marrow cells from this patient occurred at a time during which the cells from other patients were producing colonies in methylcellulose, and thus was not due to the culture system, but was an intrinsic property of the cells from this patient.
Thus, all of the PCR data available for this patient is on whole populations of cells, not on colonies. Nonetheless, the marrow and peripheral blood cells were analyzed by the double RT-PCR assay, which involves reverse transcription, splitting of cDNA into two halves, and sequence amplification by PCR with two sets of primers, one with bcr-ab11 ACTIN and another with the NE0 primers (NE0 is a viral marker gene).
As shown in Table 3 , the cells from the peripheral blood and bone marrow were positive for the NE0 retroviral gene in the immediate posttransplant period. From day 37 through day 97 posttransplant, the peripheral blood was negative for NEO-positive cells by RT-PCR, and the bone marrow was negative for NE0 coding sequences from day 37 through day 83. During this time, the patient remained in second chronic phase, with all of the cells scoring positive for the Ph translocation by classical metaphase cytogenetics. (The sensitivity of the RT-PCR assay was at the level of detection of 1 leukemia cells in 100,000 cells). During all of this time, the level of blasts was below 5% in the bone marrow.
NEO-positive cells began to reappear in the bone marrow starting at 97 days posttransplant and starting at 129 days in the peripheral blood posttransplant. At this time, the patient was still in second chronic phase, but by day 159, the lymphoblasts had returned, and were >95% of the peripheral blood and marrow. At the time of the reappearance of the NE0 positivity at 129 days, all of the cells were Ph' by metaphase cytogenetics, suggesting that at least some of these cells were NEO-positive. At the return of the lymphoblast crisis, the RT-PCR assay for the NE0 became strongly positive, a time when >95% of the cells were composed of blasts. Thus, these data suggest that the cells that were NEO-positive at the time of the return of the blast crisis were NEO-positive, and that the conversion of the RT-PCR assays in the peripheral blood and bone marrow were predictive of the clinical conversion to lymphoid blast crisis, which occurred approximately 1 month following the return of the NE0 positivity in the peripheral blood and bone marrow.
These data suggest provisionally that the return of lymphoid blast crisis at 159 days posttransplant, was at least in part due to the presence of some blast crisis cells in the infused marrow, and that in certain blast crisis patients, there is a need for negative selection of blast cells following the CD34 selection. This patient died 2 months later in fulminant blast crisis with pneumonia. His death was not related to the retroviral marking nor to the transplant. As shown in Table  3 , the bone marrow cells showed evidence of the retroviral sequences before transplant and immediately after CD34 selection and transduction.
Direct assay of the peripheral blood and marrow of the cells drawn from the patient at various times following the transplant showed that the PCR assay was positive for the NE0 marked cells during the first month after transplant but then became negative (see Table 3 and Fig 3) . Four months after transplant, the peripheral blood and marrow cells once again became positive for the N E 0 viral sequences.
Description of patient no. 2. This patient is a 27-yearold woman diagnosed in June 1990 with Ph+ chronic phase CML during a routine white blood cell count during her pregnancy. She was initially treated with hydroxyurea and interferon following interruption of her pregnancy. She had no sibling or unrelated matched allograft donors. Her disease was initially resistant to treatment and at the time of admission to M.D. Anderson, her platelet count was 897,0001pL. Two years after diagnosis, the patient was noted to be in the accelerated phase of CML, with 10% blasts in the marrow, over 50% of basophils in the peripheral blood, and a platelet count of 2,1OO,OOO/pL. The patient then received fludarabine, cytosine arabinoside, and mitoxantrone chemotherapy in an attempt to induce a second chronic phase.
Six weeks were required to recover to reach a total WBC count of 500/pL following FAM chemotherapy. At this time, peripheral blood mononuclear cells were collected and CD34 selected. Three weeks later, the marrow was harvested. CD34 selected, and one third of it marked with virus. The peripheral blood and marrow cells were 100% Ph', and the platelet count was 243.000/pL. The patient was transplanted with CD34 selected unmarked peripheral blood cells and with CD34 selected marrow cells, 30% of which had been subjected to the marking procedure. An absolute neutrophil count of S00/pL was achieved on day 25 following infusion of the unmarked CD34 selected cells and infusion of the CD34 selected virally marked marrow cells. The patient was discharged from the hospital and went home 2 to 3 days later.
Results of RT-PCR studies for N E 0 in patient no. 2. As shown in Fig 4, this patient achieved an absolute neutrophil count of 500/pL 25 days posttransplant, and was in a major cytogenetic remission (10% Ph' cells) initially, but the percentage of Ph' cells gradually rose to 80%. The patient relapsed into accelerated phase 6 months after the transplant. As shown in Fig S and in Table 4 , the RT-PCR assay showed the presence of hcr-ah/-positive NEO-positive cells and hcrahl-negative NEO-positive cells for over 6 months after transplant in this patient. As shown in Table 5 , the absolute For personal use only. on October 30, 2017. by guest www.bloodjournal.org From posttransplant (in both normal and Ph+ populations). This data showed that the conditions of transduction were sufficiently efficient that the normal and Ph+ cells that were positive for the viral response persisted for at least 150 days (see Table 5 ).
In order to formally test if the N E 0 gene marker from the virus was present in the myeloid Ph+ CML cells at 150 days posttransplant, we used FACS double color sorting to preparatively isolate the leukemia cells. As shown in Fig 6 , the leukemia cells were positive for CD33 and CD7, a marker combination that was not present on the normal cells in this patient. In order to be sure that no T cells contaminated this population, we incubated these FACS sorted cells in Dexter culture with dexamethasone for 7 days and then plated them in methylcellulose. The colonies were picked individually at 14 days and then the double PCR for NE0 and bcr-ab1 was used to test for the N E 0 gene in the Ph+ cells. As shown in Fig 7, the bcr-abl-positive colonies were also positive for the N E 0 gene.
In addition, the frequency of the NEO-positive cells, which was seen in the CD33 CD7 selected cells, was the same as that seen in the initially transduced population. (The CD33 CD7 selected cells were only 13% of the total). This data conclusively proves that at least some of the cells that contributed to the relapse arose from the marrow.
DISCUSSION
The measurable transduction frequency of the long-term culture initiating cells is surprising in view of the limiting transduction conditions (no growth factors and no stroma). These results mirror those developed at St Jude Children's Research Hospital in the laboratory of Malcolm The patients in these studies, as was the case of the patients of Brenner, were heavily pretreated with chemotherapy, and were recently exposed to chemotherapy immediately before DEISSEROTH ET AL the collection of the peripheral blood or bone marrow cells. The novel feature of our study was that the cells for marking and autologous transplant were collected immediately following chemotherapy and CD34 selected before transduction, whereas in the studies of Brenner, the cells were collected long after the conventional dose induction therapy and were not CD34 selected. This suggests that the percentage of cells that are in cycle in these heavily pretreated patients promoted the integration of the retrovirus in the earlier precursor cells. In addition, this work suggested that the means are at our disposal to modify sufficient percentage of cells to generate durable and significant levels of genetically modified cells.
The preclinical transduction studies, summarized in Table  2 , show that the transduction frequency of these cells is For personal use only. on October 30, 2017. by guest www.bloodjournal.org From approximately 1% to 10%. In addition, culture of the CD34 selected cells in Dexter culture for up to 61 days between the marking and plating in methylcellulose, permitted us to test if the NE0 sequences were being introduced into the LTCIC and other earlier cells. This proved to be the case. Finally, the NEO-positive cells persisted in the peripheral blood and marrow for at least up to 6 months following transplant, and Brenner et al have reported in AML patients, that the NEO-positive cells persisted for up to 1.5 years following transplant.
Since the transduction conditions in both of these studies did not involve growth factors or stromal, it is surprising that such early cells, as indicated by the Dexter results, and by the persistence of the NE0 marked cells for so long after transplant, were transduced by these conditions. It has been proposed by Brenner that the heavy chemotherapy exposure of these patients reduced the numbers of early precursor cells, and recruited them into cycle in greater numbers than is the case in individuals in whom no chemotherapy has been administered.
The data presented in this report showed that there were sufficient numbers of leukemia cells present in the autolo-3075 gous marrow that contributed to relapse after autologous transplant. We have made the following conclusions based on this data. The marked cells that were part of the blast population in patient no. 1 returned at the time of relapse suggesting that residual blast cells were left in the marrow infused after the CD34 selection and contributed to relapse. In addition, the Ph' chronic phase cells, which reappeared after transplant in the accelerated phase patient no. 2, were shown to be positive for the NE0 gene. We were able to isolate the bcr-ab/-positive cells by their unique immunophenotype before PCR analysis for the NE0 gene. These studies showed that the Ph' cells from the patient's transplanted cells contained the NE0 gene. Thus, the marking procedure showed that sufficient numbers of Ph' cells were left in the transplanted marrow so as to contribute to relapse. In addition, the marking procedure fulfilled the purpose for which it was designed (to identify if the relapse was contributed to, at least in part, by leukemic cells left in the autologous cells after ex vivo fractionation). This data suggest that it is necessary to use ex vivo fractionation in blast crisis cases. Both of the normal and chronic phase cells were marked in patients no. 1 and 2 up to 6 months following transplant. This shows that our retroviral marking procedures are capable of modifying sufficient numbers of progenitor cells for sustained positivity posttransplant. We will continue to follow patient no. 2 for the fate of the diploid marked cells. The patient is in a partial cytogenetic remission and is now receiving interferon posttransplant, which will continue in order to attempt to increase the number of Ph-cells.
The data reported here indicate that it will be important at least in the cases of blast crisis patients, to conduct ex vivo fractionation or "purging" procedures that supplement those measures already taken (see Table 1 ) to decrease the ratio of the Ph' to Ph-cells: namely, in vivo chemotherapy, early collection of peripheral blood progenitor cells early in the phase of hematopoietic recovery, and CD34-positive selection. The CD34 fractionation was an essential part of the transduction procedures as it was required to remove the vast excess of the terminally differentiated cells that will not contribute to the transduction, and decrease the volume of retroviral supernatant needed for transduction by decreasing the total number of cells. In addition, we have recently received permission from the Food and Drug Administration to embark on double marking trials of peripheral blood and marrow. This program may permit us to identify whether peripheral blood progenitors in the Ph' or Ph-populations. collected early in the phase of hematopoietic recovery after conventional dose chemotherapy, are sufficiently active to integrate retroviruses.
Several options exist for removal of the Ph' cells, all of them experimental. Verfaille et a1'" have reported that the immunophenotype of the diploid cells, which may be used to separate them from the CML cells, is that of a CD34-positive lineage negative DR-negative light density cell (by elutriation). Barnett et al suggest that a separation can be achieved by incubation of the cells in long-term bone marrow culture." All of these methods are possibilities and several investigators, including ourselves, are committing resources to these methods. The marking program will be the definite
